// App-Quantinova.ai

4081 : Preliminary results of molecular screening for FGFR alterations (alts) in the RAGNAR histology-agnostic study with the FGFR-inhibitor (FGFRi) erdafitinib.

Researchers

Presenter

  • Christophe Massard

Principal Investigators

  • Shubham Pant

  • Gopa Iyer

  • Martin H. Schuler

  • Olaf Witt

  • Shukui Qin

  • Josep Tabernero

  • Toshihiko Doi

  • Darren R. Hargrave

  • Constance Hammond

  • Shonda Marie Little

  • Qi Xia

  • Jing Cao

  • Ademi E. Santiago-Walker

  • Hussein Sweiti

Medical Centers

  • Gustave Roussy-Department of Therapeutic Innovation and Early Trials (DITEP), Paris, France

  • The University of Texas MD Anderson Cancer Canter, Houston, TX

  • Memorial Sloan Kettering Cancer Center, Port Washington, NY

  • West German Cancer Center, University Hospital, Essen, Germany

  • Hopp Children’s Cancer Center (KiTZ), University of Heidelberg and German Cancer Research Center, Heidelberg, Germany

  • The Chinese People's Liberation Army 81 Hospital, Nanjing, China

  • Vall d Hebron University Hospital (HUVH) and Vall d'Hebron Institute of Oncology (VHIO), Barcelona, Spain

  • National Cancer Center, EPOC, Chiba, Japan

  • Great Ormond Street Institute of Child Health, UCL, London, United Kingdom

  • Janssen Research and Development, LLC, Spring House, PA

  • Janssen Research and Development, LLC, Spring House, PA

Locations

  • France

  • United States

  • Germany

  • China

  • Spain

  • Japan

  • United Kingdom

Companies

  • N/A

Study Components

Therapeutic Area

  • Oncology (ONC)

Disease

  • Solid malignancies

Biomarkers

  • N/A

Drug/Treatment

  • N/A

Outcome

  • N/A

Study Design

  • N/A

Phase

  • II

Study Id's

  • NCT04083976

Sponsors

  • N/A

Result

  • N/A

Copyright © 2026. QuantiNova All rights reserved